Companies/Viracta Therapeutics, Inc.

Company profile

Viracta Therapeutics, Inc.

OTC: VIRX · Healthcare · Biotechnology

PublicHQ Cardiff-by-the-Sea, CACIK 0001061027Reports USD

#1019 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH —DQ 58GM —SS 49

v0.1 · 25/100 weight · pillars only

↑ disclosure history, listing tenure · ↓ operating margin, net margin

Methodology →

Revenue TTM

$738.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$51.1M

Employees

Market cap

$388.7k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$120.0k$120.0k2020

Net income-$51.1M-$51.1M2023

Operating income-$50.7M-$50.7M2023

Total assets$56.7M$56.7M2023

Liabilities$38.4M$38.4M2023

Equity$18.3M$18.3M2023

Revenue trend

FY2016 – FY2020 · USD

$610.0k

FY16

$610.0k

FY16

$2.5M

FY16

$669.0k

FY17

$669.0k

FY18

$237.0k

FY18

$2.1M

FY19

$120.0k

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Viracta Therapeutics, Inc. booked $120.0k in FY2020 revenue, contracting 94% year over year — among the slowest-growing Healthcare companies we track, at a -42548.3% net margin.

Peers · Healthcare

Actavia Life Sciences, Inc.——Biocure Technology Inc.——ProPhase Labs, Inc.38D Southern Home Medical, Inc.——

Key facts

CEOCraig R. Jalbert

SectorHealthcare

IndustryBiotechnology

HeadquartersCardiff-by-the-Sea, CA

ExchangeOTC: VIRX

Employees26

IPO date2005-09-27

Latest filings

8-K2025-02-05 8-K2025-01-31 8-K2025-01-24 8-K2025-01-17 8-K2024-12-26 8-K2024-11-29 8-K2024-11-22 10-Q2024-11-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.